Foundation News

Japanese Ecuilizumab Trial for GBS

A new treatment with compliment inhibition improves motor function in Guillain- Barré syndrome: Japanese eculizumab trial for Guillain- Barré syndrome (JET-GBS) Recent basic studies on the pathophysiology of Guillain- Barré syndrome (GBS) have shown that complement activation has a major role on peripheral nerve damage in GBS. Eculizumab (Alexion Pharmaceuticals Inc) is a humanized monoclonal antibody…

IMAGiNe study

IgM paraprotein associated polyneuropathy is a slowly progressive disease with numbness or tingling of arms and legs and severe imbalance. Occasionally, tremors and weakness are present. These symptoms are disabling, but difficult to measure. In addition, the disease is relatively rare, not very well-known, and there is no cure available. The IMAGiNe study aims to…

CSL Behring Announces FDA Approval of Privigen®

CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults KING OF PRUSSIA, Pa., Sept. 14, 2017 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the treatment of…

Charity Navigator Names GBS|CIDP Foundation as ‘Charity Worth Watching’

10 Charities Worth Watching Many of America’s most effective charities are also household names. But some well-known charities are less effective than you’d think, while a number of lesser known charities are truly exceptional. These 10 charities all operate on less than $2 million a year, but they all earn a four-star rating from Charity Navigator….

Announcing the 2017 GBS|CIDP Foundation Grant Awardees

2017 GBS|CIDP Foundation Grant Awardees (#1) Title of the project: Enhance Peripheral Nerve Repair by Modulating Macrophage Subsets Investigator: Gang Zhang, M.D; Ph.D Assistant Professor of Neurology University of Texas, Health Sciences Center at Houston Synopsis: Intravenous immunoglobulin (IVIg) is now the first-line therapy for Guillain-Barré syndrome (GBS). However, there are many disadvantages including high cost, supply…

Marketplace Access Project Applauds Bipartisan Letter from 181 Members of Congress Urging HHS to Protect Life-Saving Charitable Patient Assistance

Letter Introduced by Reps. Kevin Cramer (R-ND) & Doris Matsui (D-CA) Seeks to Protect Quarter of a Million Americans Who Depend on Charitable Assistance for Access to Critical Healthcare WASHINGTON, D.C. (May 31, 2017) – The Marketplace Access Project (MAP), a group of leading national patient advocacy organizations dedicated to protecting non-profit insurance premium and…

GBS|CIDP Foundation International 2017 Benson Clinical Research Fellowship

GBS|CIDP Foundation International 2017 Benson Clinical Research Fellowship   The GBS|CIDP Foundation International is pleased to announce a competition for the second Benson Clinical Research Fellowship.  The aim of the scheme is to provide funds (up to $150k per year for three years) to enable clinicians or non-clinical scientists in training or having recently completed training…

Largest Ever CIDP Clinical Study Completed

Largest Ever CIDP Clinical Study Completed PATH study evaluated subcutaneous immunoglobulin efficacy and safety for treating Chronic Inflammatory Demyelinating Polyneuropathy KING OF PRUSSIA, Pa. – 01 March 2017 – Global biotherapeutics leader CSL Behring announced today that it has completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as PATH (Polyneuropathy And Treatment…

GBS|CIDP Foundation International Named to the 2016 Classy 100

GBS|CIDP Foundation International Named to the 2016 Classy 100 Recognized as a consistent growing nonprofit on the leading online fundraising platform in 2016   Narberth, Pennsylvania –  GBS|CIDP Foundation International made this year’s Classy 100 list, an annual compilation of the growing nonprofits on Classy, the world’s leading online fundraising platform for social enterprises. Classy…

Our Executive Director, Lisa Butler’s Interview in PPTA Winter Newsletter

Can you tell me about the GBS|CIDP Foundation and the work you do? We were founded 35 years ago by Estelle Benson. Her husband, Bob Benson, was diagnosed with GBS and when she went to look for information and support services for this rare condition, nothing existed. She vowed that she would do something about…

7th Interlaken Leadership Awards

  Interlaken Leadership Awards The Interlaken Leadership Awards support original research in the field of neuroimmunology. Investigators whose proposals are approved by the review committee will receive monetary grants and/or drug supply. The size of the individual grants is not predetermined, in order to accommodate a wide variety of investigator needs. However small innovative trials…

GBS|CIDP Pop Up Shop Now Open!

New in 2016! At the GBS|CIDP Foundation we are proud to be a part of such an amazing & supportive group! What better way to display that pride than with some wearable goodies! Supplies are limited! All prices include US Shipping (if International – Please also include the ‘International Shipping’ option at check out. Hanes…

The Access to Marketplace Insurance Act (H.R. 3742)

  Access to Marketplace Insurance Act (H.R. 3742) This bill amends the Patient Protection and Affordable Care Act to require health insurers to accept, on behalf of individuals enrolled in qualified health plans, payments made by certain third parties, including state and federal government programs, Indian tribes, tribal organizations, urban Indian organizations, and certain tax exempt…

Pagination